CASI - CASIファ―マシュ―ティカルズ (CASI Pharmaceuticals Inc.) CASIファ―マシュ―ティカルズ

 CASIのチャート


 CASIの企業情報

symbol CASI
会社名 CASI Pharmaceuticals Inc. (CASIファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エントレメッド(EntreMed Inc.)は臨床段階の医薬品会社。同社の薬品候補「ENMD-2076」はがん治療用のオーロラAと血管新生キナーゼ阻害剤である。「ENMD-2076」は進行性固形腫瘍、多発性骨髄腫、白血病の患者での第I相試験を完了した、プラチナ抵抗性再発卵巣癌の患者での多施設共同第II相試験を行うためにデータを完了している。同社のほかの薬品候補は関節リウマチの治療用の「2-methoxyestrdiol」(2ME2 Panzem)、「ENMD-1198」及び「MKC-1」を含む。「ENMD-2076」は新規経口で有効な、オーロラAと血管新生キナーゼ阻害剤であり、癌や炎症性疾患にリンクされるオーロラAおよび複数のチロシンキナーゼに対して強力な活性を有する。  CASIファ―マシュ―ティカルズは、米国の製薬会社。癌および他の疾患の治療薬を開発する。臨床段階にある主要な医療薬候補は、癌治療のオ―ロラAと血管新生キナ―ゼ阻害剤「ENMD-2076」である。そのほか、慢性関節リウマチ治療の経口活性化合物「2-methoxyestrdiol」と経口活性小分子の細胞周期阻害剤「MKC-1」を開発する。   CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
本社所在地 9620 Medical Center Drive Suite 300 Rockville MD 20850 USA
代表者氏名 Wei-Wu He 魏偉
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 240-864-2600
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 50人
url www.casipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/casi
adr_tso
EBITDA EBITDA(百万ドル) -15.27928
終値(lastsale) 3.78
時価総額(marketcap) 327314921.22
時価総額 時価総額(百万ドル) 284.01930
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 218.08174
当期純利益 当期純利益(百万ドル) -16.11213
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CASI Pharmaceuticals Inc revenues was not reported. Net loss increased from $4.1M to $9.5M. Higher net loss reflects General and administrative - Gross increase from $1.2M to $5.2M (expense) Research and development -Gross increase of 25% to $3.3M (expense) Change in fair value of contingent right decrease from $3K (income) to $0K.

 CASIのテクニカル分析


 CASIのニュース

   Thinking about buying stock in Trillium Therapeutics, Vivos Therapeutics, Axsome Therapeutics, Orphazyme, or CASI Pharmaceuticals?  2021/08/23 12:30:00 Benzinga
NEW YORK , Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRIL, VVOS, AXSM, ORPH, and CASI. Full story available on Benzinga.com
   CASI Pharmaceuticals - Evomela sales drive guidance upgrade  2021/08/19 11:00:49 Edison Investment Research
CASIs Q221 results were driven by strong sales momentum in Evomela, its proprietary formulation of melphalan for multiple myeloma (MM) in China. The in-clinic pipeline continues to make steady progress, led by CNCT19 (CD19 targeting CAR-T therapy for B-ALL and B-NHL) nearing completion of pivotal Phase II studies. We have raised our FY2123 revenue estimates, as well as peak sales potential for Evomela, acknowledging its rapid growth in the past few quarters and CASIs guidance upgrade for 2021. Our valuation ($4.07/share versus $3.56/share previously) also sees an uptick from the increased probability of success (from 10% to 30%) for CNCT19, offset by lower net cash.
   Do Analysts Think You Should Buy: Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS), CASI Pharmaceuticals, Inc. (NASDAQ:CASI)  2021/08/17 20:59:25 Stock Equity
Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) with the stream of 5.95% also noticed, India CASI Pharmaceuticals, Inc. (NASDAQ:CASI) encountered a rapid change of -3.20% in the last hour of Tuesdays trading The post Do Analysts Think You Should Buy: Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS), CASI Pharmaceuticals, Inc. (NASDAQ:CASI) appeared first on Stocks Equity .
   CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q2 2021 Results - Earnings Call Transcript  2021/08/13 15:59:10 Seeking Alpha
   CASI Pharmaceuticals EPS beats by $0.02, beats on revenue  2021/08/12 11:22:08 Seeking Alpha
   Most Prominent Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Matinas BioPharma Holdings, Inc. (AMEX:MTNB)  2021/07/18 22:12:15 Stock Equity
CASI Pharmaceuticals, Inc. (CASI) with the stream of -3.73% also noticed, India Matinas BioPharma Holdings, Inc. (MTNB) encountered a rapid change of -2.70% in the last hour of trading session. The post Most Prominent Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Matinas BioPharma Holdings, Inc. (AMEX:MTNB) appeared first on Stocks Equity .
   Stock Mover: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Golden Minerals Company (AMEX:AUMN)  2021/07/16 21:45:22 Stock Equity
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with the stream of -1.12% also noticed, India Golden Minerals Company (AMEX:AUMN) encountered a rapid change of -2.22% in the last hour of Fridays trading session. The post Stock Mover: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Golden Minerals Company (AMEX:AUMN) appeared first on Stocks Equity .
   Stocks Stunning Activities: Gran Tierra Energy Inc. (AMEX:GTE), CASI Pharmaceuticals, Inc. (NASDAQ:CASI)  2021/07/11 20:56:31 Stock Equity
Gran Tierra Energy Inc. (GTE) with the stream of 2.06% also noticed, India CASI Pharmaceuticals, Inc. (CASI) encountered a rapid change of 2.19% in the last hour of Fridays trading The post Stocks Stunning Activities: Gran Tierra Energy Inc. (AMEX:GTE), CASI Pharmaceuticals, Inc. (NASDAQ:CASI) appeared first on Stocks Equity .
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   Alarming Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), SunLink Health Systems, Inc. (AMEX:SSY)  2021/07/02 00:41:23 Stock Equity
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with the stream of -2.90% also noticed, India SunLink Health Systems, Inc. (AMEX:SSY) encountered a rapid change of -10.82% in the last hour of Thursdays trading The post Alarming Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), SunLink Health Systems, Inc. (AMEX:SSY) appeared first on Stocks Equity .
   Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI)  2021/06/10 19:25:22 Smarter Analyst
Oppenheimer analyst Leland Gershell assigned a Buy rating to CASI Pharmaceuticals (CASI) today and set a price target of $5.00. The post Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst .
   Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI)  2021/06/10 12:35:22 Smarter Analyst
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on CASI Pharmaceuticals (CASI), with a price target of The post Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst .
   CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma  2021/06/10 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose
   CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He , Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference
   Return On Capital Employed Overview: CASI Pharmaceuticals  2021/05/21 16:43:31 Benzinga
CASI Pharmaceuticals (NASDAQ: CASI ) reported Q1 sales of $5.74 million. Earnings fell to a loss of $15.60 million, resulting in a 1.97% decrease from last quarter. In Q4, CASI Pharmaceuticals brought in $4.82 million in sales but lost $15.91 million in earnings. Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 CASIファ―マシュ―ティカルズ CASI CASI Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)